Generation Investment Management Reduces $159M in Thermo Fisher Scientific Inc. ($TMO)
Key Points
- Generation Investment Management changed its Thermo Fisher Scientific Inc. ($TMO) stake by 30.4% last quarter, cutting to 773,600 shares worth $363.08 million.
- Wall Street's consensus rating on $TMO is Buy and an average price target of $599.19.
- $TMO last traded around $469.34.
Generation Investment Management reduced its position in Thermo Fisher Scientific Inc. ($TMO) by 30.4% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 773,600 shares of Thermo Fisher Scientific Inc. after selling 337,727 shares during the quarter. Generation Investment Management's holdings in Thermo Fisher Scientific Inc. were worth $363.08 million as of its most recent filing.
Thermo Fisher Scientific Inc. ($TMO) Stock
Thermo Fisher Scientific Inc. Earnings
Thermo Fisher Scientific Inc. Dividend
Analysts Set New Price Targets
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.